Leerink Swann Initiates Coverage of Fluidigm

The investment firm gave Fluidigm an "Outperform" rating and a valuation of between $17 and $18.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.